Key Highlights

  • Three APAS Independence sales were completed and fully invoiced in Q1 FY27 with existing customers Novo and AstraZeneca.
  • A new Top-20 global pharmaceutical company is expected to begin a paid evaluation in Q2 FY27, taking the base of large global pharmaceutical customers to 9.
  • Two existing global pharmaceutical customers are each expected to move to a purchase, with purchase orders anticipated during Q2 FY27.
  • H1 FY27 sales and new evaluations are expected to reach 8 units, matching the 8 units sold to pharma in full-year FY26.

Clever Culture Systems Ltd (ASX:CC5) completed three sales of its APAS Independence instrument in the first quarter of FY27, all fully invoiced and made to existing customers Novo and AstraZeneca. The Adelaide-based company, which supplies AI-driven microbiology automation, also reported a growing list of pharmaceutical customers and evaluations, a new distribution partnership with PSC Biotech and an expectation that sales and new evaluations in the first half of FY27 will reach 8 units, the same as full-year FY26 sales to pharma.

New Top-20 Evaluation and Customer Base

Clever Culture expects to finalise a contract in the second quarter of FY27 with a new Top-20 global pharmaceutical company to start a paid evaluation of APAS Independence. Evaluations assess the instrument's analytical performance and its suitability for wider use across a customer's global drug manufacturing network, in line with the company's land-and-expand sales strategy.

If the evaluation proceeds as expected, nine pharmaceutical companies will have purchased, started paid evaluations of or be actively evaluating the instrument. The company describes that base as a foundation for potential multi-site deployments. Clever Culture described the instrument's deployments and paid evaluations as the base for customer validation and adoption across multiple manufacturing sites.

Procurement Discussions and Purchase Commitments

Final procurement discussions are under way with two existing global pharmaceutical customers as they complete their evaluations. Each is expected to progress to a purchase, with purchase orders anticipated during Q2 FY27 and invoicing expected within the same quarter. The company said these sales could open further opportunities across two global networks.

A purchase commitment from a new single-site pharmaceutical manufacturer is in its final stage, with installation and qualification planned before the end of the 2026 calendar year. The opportunity began at the APAS discovery day held at AstraZeneca in June 2026 and has since moved through the sales process.

CEO and Managing Director Brent Barnes said the timing of sales conversion will vary from quarter to quarter and that the focus remains on turning evaluations into purchases and supporting deployment across customers' manufacturing networks. He linked this to growing the installed base and expanding recurring software revenue.

PSC Biotech Channel and Customer Webinars

The recently announced partnership with PSC Biotech adds a further commercial sales channel, including a commitment to purchase an instrument. It extends Clever Culture's reach to regional and single-site pharmaceutical manufacturers.

The company also held customer insights webinars featuring Craig Stephens, Global Head of Quality Control Operations at CSL, and Karen Capper, Global Head of Microbiology, Science and Technology at AstraZeneca. The presenters discussed their experience with the technology and their vision for deployment across their companies. Topics included patient safety, manual environmental monitoring processes and the data integrity concerns attached to them, payback from the instrument, and a validation strategy completed centrally before scaling to global sites. A five-minute highlight video and the full presentations are available on the company website.

Where the Quarter Leaves Clever Culture

Clever Culture ended the quarter with three completed and invoiced sales, one new Top-20 paid evaluation expected in Q2 FY27, two existing customers moving toward purchase and a new channel through PSC Biotech. Together, these items underpin the company's expectation of 8 units of sales and new evaluations in the first half of FY27, led by global pharmaceutical companies. APAS Independence is described as the only US FDA-cleared artificial intelligence technology for automated culture plate reading, with Thermo Fisher Scientific as exclusive distributor to clinical customers in the United States and selected European countries. The instrument is currently sold to microbiology laboratories in pharmaceutical manufacturing for reading environmental monitoring culture plates, and to clinical laboratories as an in vitro diagnostic for infectious diseases.